Moderna Stocks List

Moderna Stocks Recent News

Date Stock Title
Mar 28 MRNA Moderna (MRNA) Posts Pipeline Progress, Secures Blackstone Funding
Mar 28 MRNA Apellis Pharmaceuticals (APLS) Down 8.7% Since Last Earnings Report: Can It Rebound?
Mar 28 MRNA Biotech Stock Roundup: PRAX, VKTX Up on Study Results & MRNA, REGN Give Updates
Mar 28 MRNA Better Cathie Wood Stock: Moderna vs. Intellia
Mar 27 MRNA Lukewarm Reaction To Moderna's Vaccine Day Sums Up Fine Margins In Play
Mar 27 MRNA Moderna (MRNA) Posts Upbeat Data From Next-Gen COVID Jab Study
Mar 27 MRNA Why Is Rocket Pharmaceuticals (RCKT) Down 13.6% Since Last Earnings Report?
Mar 27 MRNA Moderna CEO discusses China investment, expanding vaccines
Mar 27 MRNA US STOCKS-Wall St set to open higher as growth stocks recover
Mar 27 MRNA Moderna gets Blackstone backing for flu vaccine R&D
Mar 27 MRNA Moderna Gets $750 Million for Flu Program. Funding to Help Move Beyond Covid Vaccines.
Mar 27 MRNA Moderna wins $750M from Blackstone to fund flu program
Mar 27 MRNA UPDATE 2-Moderna secures $750 mln from Blackstone Life Sciences to develop flu shots
Mar 27 MRNA Moderna secures $750 million from Blackstone Life Sciences to develop flu shots
Mar 27 MRNA Moderna Advances Multiple Vaccine Programs to Late-Stage Clinical Trials
Mar 27 MRNA Cathie Wood's Ark Invest Continues To Double Down On Moderna, Sells Nvidia Shares
Mar 26 MRNA Moderna’s New Covid-19 Vaccine Shows Positive Results
Mar 26 MRNA Moderna succeeds in late-stage study for next-gen COVID shot
Mar 26 MRNA Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine
Mar 26 MRNA Cathie Wood's Ark Ups Tesla Bet With $28M Stock Buy Amid Rebound, Also Loads Up On This Online Game Platform
Moderna

Moderna is an American biotechnology company based in Cambridge, Massachusetts. It focuses on drug discovery, drug development, and vaccine technologies based exclusively on messenger RNA (mRNA).Moderna's technology platform inserts synthetic nucleoside-modified mRNA (modRNA) into human cells. This mRNA then reprograms the cells to prompt immune responses. It is a novel technique, previously abandoned due to the side effects of inserting mRNA into cells. As of November 2020, the Moderna COVID-19 vaccine candidate, mRNA-1273, had shown preliminary evidence of 94% efficacy in preventing COVID-19 disease in a Phase III trial, with only minor flu-like side effects. This led to its submission for emergency use authorization in Europe, the United States, and Canada.

Browse All Tags